摘要
目的 比较奥氮平与利培酮治疗首发精神分裂症的疗效及不良反应。方法 随机将符合CCMD-2R精神分裂症的诊断标准70例患者进入奥氮平或利培酮组接受治疗,分别在治疗0、1、2、4、6、8周评定PANSS和TESS量表,在0、4、8周检查心脑电图和肝肾功能,在0、8周检查血催乳素和空腹血糖。结果 奥氮平与利培酮疗效相当,奥氮平能迅速减轻精神症状,其产生的不良反应少、严重程度轻,很少引起血催乳素变化;利培酮会显著提高血催乳素水平。结论 奥氮平对首发精神分裂症治疗安全有效。
Objective: To compare efficacy and adverse effects of olanzapine and risperidone in treatment of first episode schizophrenia. Methods: 70 cases of schizophrenia met CCMD-2R criteria were enrolled and randomly assigned into olanzapine or risperidone treatment group. PANSS and TESS were rated at baseline and 1, 2, 4, 6, 8 weeks after treatment; EEC, EKG, hepatic and renal funution were examined at baseline and 4, 8 weeks after treatment. Blood prolactin and fasting blood glucose were tested at baseline and 8 week after treatment. Results: Both drugs had comparable efficacy, olanzapine relieved psychotic symptoms more rapidly with less and mild side effect and less prolaction change, while risperidone increase prolactin more significantly. Conclusion: Olanzapine shows efficacy and safety as well in treatment of first episode schizophrenia.
出处
《上海精神医学》
北大核心
2003年第6期338-340,327,共4页
Shanghai Archives of Psychiatry
